NCT02585973 2021-06-29Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCCUNC Lineberger Comprehensive Cancer CenterPhase 1 Completed12 enrolled
NCT02906059 2020-10-12Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerNYU Langone HealthPhase 1 Completed7 enrolled
NCT02508246 2019-03-13WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and NeckUniversity of WashingtonPhase 1 Completed12 enrolled